
Releases
Curis Expands TakeAim CLL Study Sites and Secures Reverse Split Approval
Curis, Inc. has officially opened eleven clinical sites for its Phase 2 TakeAim CLL study, marking a significant step in testing emavusertib alongside zanubrutinib. Simultaneously, the company’s shareholders have approved a reverse stock split, a strategic move designed to help the firm regain compliance with Nasdaq’s minimum bid price requirements.

























